MacuMira: A Breakthrough in Dry AMD Treatment

More Than 200 Million People Live with Dry AMD Worldwide

Until now, there has never been a proven solution to improve vision loss from dry AMD. MacuMira changes that.

MacuMira is Canada’s first and only clinically proven treatment for dry age-related macular degeneration. This safe, painless, noninvasive therapy can be delivered in short appointments at local eye care clinics. Clinical results showed patients experienced improved visual clarity in just 10 days.

Discover how MacuMira is helping Canadians living with dry AMD see more clearly.

Learn More About MacuMira for Dry AMD

MacuMira: Changing the Story of Dry AMD

Dry age-related macular degeneration (AMD) doesn’t just affect your vision; it affects how you live. From losing independence to missing out on everyday details, the impact can be profound. 

Historically, management focused only on slowing progression. Now, with MacuMira, there’s a clinically supported way to help improve how you see.

MacuMira is a first-of-its-kind solution authorized by Health Canada to improve visual function in people living with dry AMD. It’s safe, comfortable, and designed to fit easily into the clinical care experience.

Your sight and your quality of life matter. MacuMira is here to support you every step of the way.

How MacuMira Works

Microcurrent Stimulation

MacuMira delivers low-level microcurrent through the eyelids to stimulate retinal activity. This approach is grounded in decades of medical use and has been adapted for the specific needs of dry AMD.

Clinically Improved Vision

A clinical trial demonstrated that 100% of patients experienced improved visual function after receiving 6 treatments over a 30-week period. On average, patients showed improved visual acuity (as assessed by the ETDRS, which measures the number of letters read) and contrast sensitivity within 4 weeks of the first treatment. With continued treatment, vision may be maintained indefinitely.

Noninvasive & Comfortable

MacuMira requires no injections, medication, lasers, or surgery. Patients simply visit their eye care provider on a prescribed schedule, relax while wearing the MacuMira device for approximately half an hour, and then continue with their day.

Download the Clinical Trial

The MacuMira clinical trial, published in the International Journal of Retina and Vitreous, found the following:

100%

of patients in the treatment group showed improved vision

48%

of patients improved by at least 10 letters on the ETDRS acuity chart

8.2 ETDRS letters

Average improvement, along with a 25% average increase in ETDRS acuity

0

adverse effects of treatment

100%

of treated patients maintained their vision improvements for the duration of the trial

During the trial period, placebo group participants’ visual acuity decreased by 2 ETDRS letters read on average.

Real Patient Experiences

instagram facebook facebook2 pinterest twitter google-plus google linkedin2 yelp youtube phone location calendar share2 link star-full star star-half chevron-right chevron-left chevron-down chevron-up envelope fax